Concepedia
Statistics
Publications
36
Citations
2.8K
H-Index
26
Active since
1986
Affiliations
National Cancer Institute(Current)
National Institutes of Health
National Cancer Institute
Novartis (Switzerland)
National Institutes of Health Clinical Center
David Köhler is an author at National Cancer Institute specializing in medicine, pharmacology, and oncology.
Publications per year
1986–2022
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
W D Figg, William Dahut, Paul H. Duray et al. · PubMed · 2001 · 304 citations
Medicine, Pharmacology, Pharmacotherapy +13
Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer
J. Zujewski, Ivan D. Horak, C.J. Bol et al. · Journal of Clinical Oncology · 2000 · 265 citations
Medicine, Oncology, Pharmacology +15
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
Wyndham H. Wilson, G Bryant, Susan E. Bates et al. · Journal of Clinical Oncology · 1993 · 246 citations
Medicine, Oncology, Pharmacology +17
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.
V. Sandor, Virginia Stark-Vancs, Deborah A. Pearson et al. · Journal of Clinical Oncology · 1998 · 237 citations
Medicine, Oncology, Radiation Oncology +17
Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
Michelle A. Rudek, William D. Figg, Valerie Dyer et al. · Journal of Clinical Oncology · 2001 · 158 citations
Pharmacy, Oncology, Pharmacology +15
1–5 of 36